JNJ-39393406

JNJ-39393406
Clinical data
Routes of; administration	By mouth
Drug class	Antinicotinic
Identifiers
	IUPAC name 3-[3-[(2,2-Difluoro-1,3-benzodioxol-5-yl)amino]-5-pyridin-4-yl-1,2,4-triazol-1-yl]-N,N-dimethylpropanamide;
CAS Number	953428-73-4;
PubChem CID	16755766;
ChemSpider	28424208;
UNII	T930SOU82P;
ChEMBL	ChEMBL3545291;
CompTox Dashboard (EPA)	DTXSID401110616 ;
Chemical and physical data
Formula	C19H18F2N6O3
Molar mass	416.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4;
	InChI InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25); Key:IURMHZBQEYNQOH-UHFFFAOYSA-N;

JNJ-39393406 is an experimental medication which is under development by Janssen Pharmaceutica, a division of Johnson & Johnson, for the treatment of depressive disorders and smoking withdrawal.^[1] It acts as a selective positive allosteric modulator of the α7 nicotinic acetylcholine receptor (nAChR).^[1] It does not act on the α4β2 or α3β4 nAChRs or the serotonin 5-HT₃ receptor, and does not interact with a panel of 62 other receptors and enzymes.^[2] The drug has been found to lower the agonist and nicotine threshold for activation of the α7 nAChR by 10- to 20-fold and to increase the maximum agonist response of the α7 nAChR by 17- to 20-fold.^[2]

As of February 2018, JNJ-39393406 is in phase II clinical trials for both depressive disorders and smoking withdrawal.^[1] It was also under investigation for the treatment of schizophrenia and Alzheimer's disease, but development for these indications was discontinued.^[1]

References

^ ^a ^b ^c ^d ^e "JNJ-39393406". Adis Insight.
^ ^a ^b Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, Rujescu D, Favis R, Sun Y, Franc MA, Ouwerkerk-Mahadevan S, Janssens L, Timmers M, Streffer JR (2013). "Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study". Neuropharmacology. 64: 197–204. doi:10.1016/j.neuropharm.2012.06.040. PMID 22766391. S2CID 29118435.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "JNJ-39393406". Adis Insight.

[pmid22766391-2] Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, Rujescu D, Favis R, Sun Y, Franc MA, Ouwerkerk-Mahadevan S, Janssens L, Timmers M, Streffer JR (2013). "Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study". Neuropharmacology. 64: 197–204. doi:10.1016/j.neuropharm.2012.06.040. PMID 22766391. S2CID 29118435.

[1]

[2]

See also

References